Massmutual Trust Co. FSB ADV Boosts Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Massmutual Trust Co. FSB ADV grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 72.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,487 shares of the biopharmaceutical company’s stock after purchasing an additional 1,887 shares during the quarter. Massmutual Trust Co. FSB ADV’s holdings in Gilead Sciences were worth $308,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Financial Counselors Inc. lifted its position in shares of Gilead Sciences by 1.5% during the 4th quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock valued at $718,000 after buying an additional 128 shares in the last quarter. Steph & Co. increased its position in Gilead Sciences by 1.9% during the fourth quarter. Steph & Co. now owns 7,548 shares of the biopharmaceutical company’s stock worth $611,000 after buying an additional 142 shares during the period. First Affirmative Financial Network grew its holdings in Gilead Sciences by 3.5% during the first quarter. First Affirmative Financial Network now owns 4,342 shares of the biopharmaceutical company’s stock worth $318,000 after acquiring an additional 147 shares during the period. Rathbones Group PLC lifted its position in shares of Gilead Sciences by 3.7% in the fourth quarter. Rathbones Group PLC now owns 4,185 shares of the biopharmaceutical company’s stock valued at $339,000 after acquiring an additional 150 shares in the last quarter. Finally, MCF Advisors LLC increased its stake in Gilead Sciences by 2.1% during the first quarter. MCF Advisors LLC now owns 7,348 shares of the biopharmaceutical company’s stock worth $538,000 after acquiring an additional 152 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Price Performance

Shares of NASDAQ GILD traded down $1.94 during trading on Monday, hitting $74.83. The company had a trading volume of 7,347,882 shares, compared to its average volume of 7,415,173. The stock has a fifty day simple moving average of $68.80 and a two-hundred day simple moving average of $70.66. The firm has a market capitalization of $93.23 billion, a price-to-earnings ratio of 208.28, a price-to-earnings-growth ratio of 3.37 and a beta of 0.18. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $87.86. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on GILD shares. UBS Group cut their target price on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. Cantor Fitzgerald cut their price target on shares of Gilead Sciences from $75.00 to $70.00 and set a “neutral” rating on the stock in a research report on Monday, July 22nd. HSBC upgraded shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price on the stock in a research note on Wednesday, April 24th. TD Cowen lowered their price objective on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Friday, April 26th. Finally, Morgan Stanley lowered their target price on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a report on Friday, April 26th. Twelve analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $81.81.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $68.63, for a total transaction of $137,260.00. Following the transaction, the insider now directly owns 96,380 shares of the company’s stock, valued at $6,614,559.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.